Skip to main content
OpenTrials
Completed

NCT Number: NCT03497000

Effects of OCTA-guided PDT in Acute CSC

OCTA-guided PDT is as safe and effective as ICGA-guided PDT in the treatment of acute central serous chorioretinopathy. Or OCTA-guided PDT is more effective than ICGA-guided PDT in the treatment of acute central serous chorioretinopathy, safe as well.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Central Serous Chorioretinopathy Eye Diseases Retinal Diseases Tomography, Optical Coherence

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

People's Hospital of Peking University

Beijing, Beijing Municipality, 100044, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Idiopathic detachment of the neurosensory retina with a focal leak at the level of the RPE with FA
  • Presence of SRF and/or serous pigment epithelial detachment on OCT
  • Presence of abnormal dilated choroidal vasculature in ICGA

Exclusion criteria

  • Patients with other ocular conditions commonly associated with SRF, such as choroidal neovascularization, polypoidal choroidal vasculopathy (PCV), diabetic retinopathy, retinal vascular occlusion, Coat's disease
  • Any disease that may affect the quality of imaging (quality of OCTA images < 6), such as cataract, high myopia or nystagmus
  • History of ocular surgeries including retinal laser
  • Pregnancy
  • Any uncontrolled systemic disease
  • Any condition rendering patients intolerable to image acquisition

Treatment and study plan

OCTA-guided Photodynamic therapy

Procedure

Half-dose photodynamic therapy using verteporfin under the guidance of OCTA

ICGA-guided Photodynamic therapy

Procedure

Half-dose photodynamic therapy using verteporfin under the guidance of ICGA

Primary outcomes

  1. Number of patients with subretinal fluid resolution on OCT after PDT of two groups

    Time frame: 3 months

Secondary outcomes

  1. Number of patients with leakage point resolution on FFA after PDT of two groups

    Time frame: 3 months

  2. Number of recurrent CSC after PDT of two groups

    Time frame: 3 months

  3. BCVA (best corrected visual acuity) at every follow-up of two groups

    Time frame: 1 month, 3 months

Sponsors and collaborators

Lead sponsor

Peking University People's Hospital

Other

Collaborators

  • National Natural Science Foundation of China

Registry information

Official study title

Effects of Optical Coherence Tomography Angiography-guided Photodynamic Therapy in Acute Central Serous Chorioretinopathy

Important dates

Study start
2017
Primary completion
2017
Study completion
2018
First posted
Apr 12, 2018
Registry last updated
Apr 17, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.